Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592741 | SCV000706772 | pathogenic | not provided | 2017-03-08 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001379040 | SCV001576762 | pathogenic | Maple syrup urine disease | 2023-10-28 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 6 of the BCKDHA gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in BCKDHA are known to be pathogenic (PMID: 16786533, 22593002). This variant is present in population databases (rs760494152, gnomAD 0.003%). Disruption of this splice site has been observed in individual(s) with maple syrup urine disease (PMID: 31980395, 33300147; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 500713). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV001379040 | SCV002033450 | pathogenic | Maple syrup urine disease | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001829666 | SCV004215923 | pathogenic | Maple syrup urine disease type 1A | 2023-12-26 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001829666 | SCV002088157 | likely pathogenic | Maple syrup urine disease type 1A | 2021-09-08 | no assertion criteria provided | clinical testing |